Helus Pharma Inc.: Venrock Healthcare Capital Partners III, L.P. amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Venrock Healthcare Capital Partners III, L.P. amended its Schedule 13G filing on Helus Pharma Inc., updating its beneficial ownership stake with the SEC under accession number 0001738048-26-000092. The filing signals a change in the venture firm's position in the pharmaceutical company, though the amended document did not disclose a revised share count or percentage in the headline details. Schedule 13G amendments are typically filed by passive investors when their ownership crosses or adjusts relative to the 5% threshold, making the update a routine but closely watched disclosure for tracking institutional backing. Investors will look to the full filing for the exact share total and any indication of whether Venrock's stake rose or fell.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Helus Pharma Inc., Venrock Healthcare Capital Partners III, L.P.